Compare Alcon AG (ALC) vs Prospect Capital Corporation (PSEC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alcon AG vs Prospect Capital Corporation — how do they compare? Alcon AG trades at $66.96 (market cap $32.69B), while Prospect Capital Corporation trades at $2.2 (market cap $1.10B). The key difference: Alcon AG is far larger — about 29.7× Prospect Capital Corporation's market cap, and Prospect Capital Corporation pays the higher dividend (22.73%). Which is the better fit depends on your goals.
| ALC | PSEC | |
|---|---|---|
Market Cap | $32.69B | $1.10B |
Sector | Health | Financials |
52-Week High | $92.22 | $3.47 |
52-Week Low | $62.02 | $2.15 |
Enterprise Value | $36.28B | — |
Dividend Yield | 0.54% | 22.73% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALC trades at $66.87, down 4.01% on the day, amid a mixed technical and fundamental backdrop. The stock exhibits a bullish technical signal overall, with moving averages supporting a positive trend, while oscillators remain neutral. Fundamentally, revenue growth is steady, reaching $10.40 billion in 2025, though net income margin compressed to 7.7%. Recent news highlights product innovation, including a collaboration with RxSight for adjustable PCIOLs, signaling ongoing R&D investment. Analyst sentiment is predominantly positive, with a consensus price target of $86.00 implying significant upside.
The outlook for ALC is cautiously optimistic, driven by new product launches and strategic partnerships that may fuel growth. However, risks include competitive pressures, macroeconomic headwinds, and margin compression. With a P/E of 40.92, the valuation appears rich relative to historical norms, requiring strong earnings delivery to justify current levels. Investors should weigh robust analyst buy ratings against execution risks and market volatility.
Prospect Capital Corporation (PSEC) trades at $2.20, down 1.79% recently, with a bearish technical outlook. The stock shows mixed fundamentals with a low P/B ratio of 0.37 but concerning negative revenue and net income margins. Recent earnings have consistently beaten expectations, with Q1 2026 EPS of $0.16 exceeding the $0.1109 forecast. The company maintains regular dividend payments, recently completing a $328 million portfolio sale that generated a 4.8x return on investment.
PSEC presents a high-risk opportunity with its deep discount to NAV and 18%+ yield attracting income investors, but fundamental deterioration and analyst skepticism pose significant challenges. The bearish technical signals and negative cash flow trends suggest caution, while the company's shift toward first-lien lending may improve portfolio quality over time. Investment suitability depends on risk tolerance for BDC volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alcon AG
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →About Prospect Capital Corporation
Prospect Capital Corp is a closed-end investment company based in the United States. Its investment objective is to generate both current income and long-term capital appreciation through debt and equity investments. The company invests primarily in senior and subordinated debt and equity of private companies for acquisitions, divestitures, growth, development, recapitalizations, and other purposes. It makes investments, including lending in private equity, sponsored transactions, directly to companies, investments in structured credit, real estate, and syndicated debt.
Read more on PSEC →
